NY-PERMUTIVE
2.11.2021 09:17:08 CET | Business Wire | Press release
Permutive , an audience platform for publishers and advertisers, which enables media to be traded in a privacy-safe way, has secured $75M in Series C from SoftBank Vision Fund 2. It brings Permutive’s total raised to date to $105M, with previous investors EQT Ventures, Octopus Ventures, and ACE & Company also participating. The funding will enable Permutive to grow its patented on-device technology and scale its Audience Platform to create a global privacy-first infrastructure for programmatic advertising, now a $155B industry.
Personal data has powered digital advertising for over ten years; its misuse has captured the attention of regulators and consumers. This reckoning has triggered a seismic power shift from adtech owned programmatic advertising to a publisher owned privacy-first web. Via Permutive's Audience Platform, which has seen a 20x growth in targeted ads in the last two years, publishers can deliver a personalized advertising experience without compromising privacy via consented first-party data. The company has built a client roster comprising some of the most highly regarded publishers in Europe and North America, including News Corp, Hearst, BuzzFeed, Penske, Future plc, The Guardian, Vox Media, Insider, Hubert Burda Media and Condé Nast International.
“Publishers are the foundation of the web, and the relationship they have with their users is the backbone of digital advertising,” says Joe Root, CEO and co-founder, Permutive . “As privacy shifts the economics of the internet towards this publisher-owned web, a privacy-first infrastructure will ensure this next iteration of digital advertising is immune to privacy chaos, will scale, and thrive.”
Advertisers are buying directly from publishers because they are a stable foundation for data-driven advertising and are trusted partners when navigating the impact of browser changes and tightening privacy regulations. But without an infrastructure to support this transition to a publisher-owned privacy-first web, the industry won't achieve scale. Permutive has created a new model for digital advertising with privacy at its core, where publishers and advertisers can own and control their data while planning and buying campaigns. This brings transparency, scale and privacy to programmatic advertising for the first time.
“To underpin a privacy-first web requires unique technology. As a leader in on-device technology, Permutive can bring a complicated landscape that’s being significantly disrupted into a privacy-safe future. The company’s technology is now running on over 1 billion devices a month globally, and we see tremendous opportunity for sustained growth as on-device processing reshapes adtech,” says Max Ohrstrand, investor for SoftBank Investment Advisers .
Permutive’s funding comes at a critical time for the digital advertising industry. Creating a privacy-first infrastructure built to protect user privacy instils trust, transparency, and efficiency in programmatic ad spending.
-ENDS-
Notes to editor:
About Permutive
Permutive is rebuilding data in programmatic advertising to protect privacy. As the only Audience Platform built on patented on-device and privacy-preserving technology, we enable premium advertisers and publishers to plan, build and activate cohorts — all while keeping everyone’s data safe.
Working with clients across Europe and North America, publishers using Permutive include News Corp, Hearst, BuzzFeed, Penske Media, Future plc, The Guardian, Vox Media, Insider, Hubert Burda Media and Condé Nast International.
Find out more at permutive.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005128/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
